Nebuliser Sales Grow Healthy as Patient Pool with Respiratory Conditions Continues to Expand
Chronic obstructive pulmonary disease (COPD) remains the third leading mortality cause globally. The world Health Organization (WHO) also reveals that while COPD accounted for over 3 million deaths in 2019, the number of asthma patients also reached as high as 262 million the same year. As revealed by the Cystic Fibrosis Foundation Patient Registry (US), over 70,000 people worldwide are currently living with cystic fibrosis, more than half of which are adults. The statistical data reflects an alarming rate of the growing burden of respiratory conditions on the healthcare system, which is in fact the strongest factor driving nebuliser sales in the global market.
The nebulisation technique is predominantly recommended for cystic fibrosis in addition to asthma, and COPD. Mounting prevalence of these conditions is thus likely to foster adoption of nebulisers during the forecast period. The market continues to thrive at a healthy rate with introduction of the variations in convenient categories such as electrically powered, and rechargeable nebulisers.
Innovations in terms of size, quality, and operation bolster adoption to a significant extent. Lightweight nebulisers have also been garnering traction among patients afflicted with chronic respiratory condition(s). Portable nebulisers, on the other hand, have been gaining ground on the back of technological advancements, frequent new launches on the market, and convenient usage feature. Towering sales within the home healthcare segment are expected to heavily contribute towards the growth of the nebuliser market. Moreover, conscious efforts by market leaders in public awareness, and patient education such as Philips’ CSR Campaign (2019), and initiatives such as the Global Alliance against Chronic Respiratory Diseases are projected to significantly encourage adoption over the forecast period. However, the persistent safety concerns around these devices regarding the potential risk of infection transmission is likely to be a longstanding challenge facing market participants looking to an exponential growth outlook.
Looking at COVID-19 Impact on Global Nebuliser Sales
The market for nebulisers exhibited a sustained growth trajectory through 2020, when the disease outbreak was peaking. While patients having respiratory difficulties initially admitted their reluctance for using inhaling medication devices, the recommendation for nebulisers, and other devices from physicians soon upheld the demand worldwide. With COVID-19 cases still prevailing in multiple parts of the world, the global focus remains on efficient control of the infection spread. Considering the notably high number of cases recording difficulty breathing/shortness of breath, respiratory devices such as metered dose inhalers, ventilators, and nebulisers will continue to gain strong ground throughout the pandemic. Life-saving medical devices continue to be in demand as there is no treatment for the disease yet. Researchers, and pharma companies are thus indulged in development of novel effective therapies that could potentially aid in COVID-19 treatment. Ampio Pharmaceuticals Inc. is even exploring the possibilities of leveraging the benefit of Ampion-based nebulised treatment in case of the acute respiratory distress syndrome induced by SARS-CoV-2.
Jet Nebulisers Continue to Top Adoption; Preference for Mesh Nebulisers Grows Apace
The mature market of nebulisers has long been witnessing the dominance of jet nebulisers, clearly owing to their cheaper price point that poses constant competition to other nebuliser types. The market continues to witness innovations coming to the fore more frequently; however, those that make and deal in nebulisers other than jet are expected to face the growing intricacies of the associated regulatory framework. Mesh nebulisers, on the other side, are likely to witness heightening demand on the back of their superior convenience quotient. Despite their expensive price point, the increasing application of mesh nebulisers in clinical trials of drug development is expected to be a strong point of indicator for them in long term. Mesh nebulisers have been gaining greater preference over their jet counterparts, as reflected by the Europe, and U.S. clinical trial databases. Easier operability, and portability of mesh nebulisers will continue to account for their ascending popularity. They tend to reduce the drug waste to a large extent, which also works to their advantage. Ultrasonic nebulisers have emerged as, and will remain a highly lucrative investment pocket for market participants. These devices are expected to continue gaining the spotlight as they enable an anaesthetic agent to be self-administered.
North America Maintains its Lead; Nebuliser Sales to Ramp up in Asia Pacific
North America’s nebuliser market size continues to hold the lion’s share in the global market. Sophisticated healthcare infrastructure, and rapid technology adoption will remain the prime drivers for the nebuliser sales within the region. High respiratory disease prevalence, and robust tobacco consumption levels, especially in the U.S., also contribute towards increasing nebuliser demand. Europe is also expected to remain an important market for nebuliser manufacturing companies as the region continues to witness an extending application of nebulisers, and other respiratory devices, spanning delivery rooms, nursing care units, and even postoperative rooms.
On the other hand, the market in Asia Pacific is buoyant on the back of an expanding elderly patient pool, favourable government initiatives, and rising emphasis on preventive healthcare across most economies. Recently, the National Pharmaceutical Pricing Authority (NPPA, India) recently declared a price cap on the five critical medical devices, which also include nebulisers besides glucometer, blood pressure machine, pulse oximeter, and digital thermometer. In the light of soaring demand in the market amid pandemic situation, NPPA authorities intend to immediately implement price regulation on these devices, and increase their affordability for the general public. This effort by a regulatory body will contribute to market growth in India to a great extent.
Key Market Players in Global Nebuliser Landscape
Some of the most prominent players in this highly competitive market include Koninklijke Philips N.V., Omron Healthcare Co., PARI Respiratory Equipment, Inc., Agilent Technologies, GF Health Products Inc., Agilent Technologies, Becton, Dickinson and Company, Covidien plc, VYAIRE MEDICAL, INC., Briggs Healthcare, Drive DeVilbiss Healthcare, Allied Healthcare Products, Inc., GE Healthcare Ltd., CareFusion Corporation, Bayer, Roche, 3M, Johnson & Johnson, Pfizer, Cook Medical, Novartis, Antares, Sanofi, Merck, and Glaxosmithkline. The first three continue to account for a major revenue share in the market. PARI’s e-FLOW technology device – LAMIRA recently received an approval for delivery of ARIKAYCE (amikacin liposome inhalation suspension) used in the mycobacterium avium complex lung disease treatment.
Nebuliser Innovations Revolve around Smart, Lightweight, Compact, and Portable Features
Innovation of intelligent/smart nebulisers has been making headlines over the recent past. While these are smartphone-connected, app-enabled respiratory devices, companies are focusing on introducing the most user-friendly features so as to appeal to both young, as well as elderly patients. The intelligent mesh nebuliser by Briutcare that was launched in 2019 is an adjustable, pocket-sized device. Earlier in 2017, a UK-based inhaled medicines specialist, Vectura Group plc also launched a smart nebuliser VR647, specifically targeting its use in a prophylactic therapy for asthmatic children. Portable nebulisers are also expected to remain a lucrative trend owing to its effective, and faster medication delivering capabilities. To gain a competitive advantage, companies are introducing device models with build-in rechargeable batteries, and are much easier to use. In line with this, Philips was the one to launch InnoSpire Go, its smallest handheld nebuliser in 2018. The device reportedly brings down the overall medical treatment time by 25%. The same year, Convexity Scientific also brought in a lightweight Flyp handheld ultrasonic nebuliser to the market.
Key Elements Included In The Study: Global Nebuliser Market
Post Sale Support, Research Updates & Offerings
We value the trust shown by our customers in Fairfield Market Research. We support our clients through our post sale support, research updates and offerings.
Under uncertainty, traditional approaches to strategic planning can be downright dangerous. True ambiguity is no basis to forecast the future – degree of risk, the magnitude of circumstances, conditions and consequences are not known or unpredictable. To avoid dangerous binary views of uncertainty; strategic posture, moves and actions through market research is the best bet.Read more